Expands U.S. MAVERIC Phase 3 Trial Network; Target recruitment anticipated by end of 2Q26, with potential to extend into Q3 to accommodate patient enrollment from the additional clinical sites
- Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital.
- Growing interest in MAVERIC is expected to support the activation of up to seven additional U.S. clinical centers, with the total number anticipated to reach 25.Patient enrollment surpassed 50% in early January and has now reached 75%.
- Target recruitment is anticipated by the end of Q2 2026, with the potential to extend into Q3 to accommodate patient enrollment from the additional clinical sites.
- MAVERIC builds on positive Phase II data and is expected to support a New Drug Application with the U.S. FDA.